UY27572A1 - Formas de sal e-2-metoxi-n-(3-(4(3-metil-4-(6-metilpiridin-3-iloxi) fenilamino) quinazolin-6-il)alil) acetamida y procedimiento de producción - Google Patents

Formas de sal e-2-metoxi-n-(3-(4(3-metil-4-(6-metilpiridin-3-iloxi) fenilamino) quinazolin-6-il)alil) acetamida y procedimiento de producción

Info

Publication number
UY27572A1
UY27572A1 UY27572A UY27572A UY27572A1 UY 27572 A1 UY27572 A1 UY 27572A1 UY 27572 A UY27572 A UY 27572A UY 27572 A UY27572 A UY 27572A UY 27572 A1 UY27572 A1 UY 27572A1
Authority
UY
Uruguay
Prior art keywords
methyl
quinazolin
phenylamine
acetamide
methylpiridin
Prior art date
Application number
UY27572A
Other languages
English (en)
Inventor
John Charles Kath
Daniel Tyler Richter
Original Assignee
Pfizer
Rafael M Roubaud
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer, Rafael M Roubaud filed Critical Pfizer
Publication of UY27572A1 publication Critical patent/UY27572A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Oncology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pulmonology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Dermatology (AREA)
  • Reproductive Health (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Sales succinato y malonato de E-2-metoxi-N-(3-{4-[3-metil-4-(6-metil-piridin-3-iloxi)fenilamina]quinazolin-6-il} alil)-acetamida de fórmula I. Particularmente la presente invención refiere: a) las sales sesquisuccinato y dimalonato de fórmula I, b) composiciones farmacéuticas que contienen las sales succinato y malonato de fórmula I; c) procedimientos de tratamiento de enfermedades hiperproliferativas tales como los cánceres en mamíferos, especialmente en seres humanos, mediante la administración de las sales anteriores y d) a procedimientos de preparación de las sales anteriores
UY27572A 2001-12-12 2002-12-09 Formas de sal e-2-metoxi-n-(3-(4(3-metil-4-(6-metilpiridin-3-iloxi) fenilamino) quinazolin-6-il)alil) acetamida y procedimiento de producción UY27572A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US34088501P 2001-12-12 2001-12-12

Publications (1)

Publication Number Publication Date
UY27572A1 true UY27572A1 (es) 2003-07-31

Family

ID=23335337

Family Applications (1)

Application Number Title Priority Date Filing Date
UY27572A UY27572A1 (es) 2001-12-12 2002-12-09 Formas de sal e-2-metoxi-n-(3-(4(3-metil-4-(6-metilpiridin-3-iloxi) fenilamino) quinazolin-6-il)alil) acetamida y procedimiento de producción

Country Status (34)

Country Link
US (1) US6844349B2 (es)
EP (1) EP1456199A1 (es)
JP (1) JP4202926B2 (es)
KR (1) KR20040065259A (es)
CN (1) CN1608062A (es)
AP (1) AP2004003059A0 (es)
AR (1) AR037772A1 (es)
AU (1) AU2002366581A1 (es)
BR (1) BR0214876A (es)
CA (1) CA2469889A1 (es)
DO (1) DOP2002000544A (es)
EA (1) EA007412B1 (es)
EC (1) ECSP045148A (es)
GE (1) GEP20063872B (es)
GT (1) GT200200272A (es)
HR (1) HRP20040530A2 (es)
HU (1) HUP0402662A2 (es)
IL (1) IL161915A0 (es)
IS (1) IS7227A (es)
MA (1) MA27095A1 (es)
MX (1) MXPA04005678A (es)
NO (1) NO20042925L (es)
NZ (1) NZ532436A (es)
OA (1) OA12735A (es)
PA (1) PA8561401A1 (es)
PE (1) PE20030716A1 (es)
PL (1) PL370858A1 (es)
RS (1) RS46404A (es)
TN (1) TNSN04112A1 (es)
TW (1) TW200301103A (es)
UA (1) UA75482C2 (es)
UY (1) UY27572A1 (es)
WO (1) WO2003050108A1 (es)
ZA (1) ZA200402995B (es)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR0214499A (pt) * 2001-12-12 2005-05-10 Pfizer Prod Inc Derivados de quinazolina para o tratamento do crescimento anormal das células
EP2280003B1 (en) 2002-07-15 2014-04-02 Symphony Evolution, Inc. Process for preparing receptor-type kinase modulators
AU2003303045A1 (en) * 2002-12-18 2004-07-09 Pfizer Products Inc. 4-anilino quinazoline derivatives for the treatment of abnormal cell growth
BR0317259A (pt) * 2002-12-19 2005-11-08 Pfizer Prod Inc Complexos de e-2-metóxi-n-(3-{4-[3-metil-4-(6-metilpiridin-3-ilóxi)-fenil amino]- quinazolin-6-il}-alil)-acetamida, seus métodos de produção e utilização
DK1628685T3 (da) 2003-04-25 2011-03-21 Gilead Sciences Inc Antivirale phosphonatanaloge
MXPA06001989A (es) * 2003-08-18 2006-05-17 Pfizer Prod Inc Programa de dosificacion para un nuevo agente anticanceroso.
SI2213661T1 (sl) 2003-09-26 2011-11-30 Exelixis Inc c-Met modulatorji in postopki uporabe
ATE517622T1 (de) * 2003-10-27 2011-08-15 Merck Sharp & Dohme Salz eines tetrahydropyranylcyclopentyltetrahydropyridopyr diderivats als ccr-2 antagonisten
US20050192298A1 (en) * 2004-02-27 2005-09-01 Pfizer Inc Crystal forms of E-2-Methoxy-N-(3-{4-[3-methyl-4-(6-methyl-pyridin-3-yloxy)-phenylamino]-quinazolin-6-yl}-allyl)-acetamide
WO2005121124A1 (en) * 2004-06-07 2005-12-22 Pfizer Products Inc. Complexes of e-2-methoxy-n-(3-{4-[3-methyl-pyridin-3-yloxy)-phenylamino]-quinazolin-6-yl}-allyl)-acetamide and methods of preparing same
US7871991B2 (en) 2004-07-27 2011-01-18 Gilead Sciences, Inc. Phosphonate analogs of HIV inhibitor compounds
JP2008542356A (ja) * 2005-06-03 2008-11-27 ファイザー・プロダクツ・インク 異常な細胞増殖の治療用の二環式誘導体
EP1896030A1 (en) * 2005-06-03 2008-03-12 Pfizer Products Incorporated Combinations of erbb2 inhibitors with other therapeutic agents in the treatment of cancer
JP5544165B2 (ja) * 2006-05-16 2014-07-09 ギリアード サイエンシーズ， インコーポレイテッド 血液悪性疾患の処置のための方法および組成物
KR20090090336A (ko) 2006-12-12 2009-08-25 다케다 야쿠힌 고교 가부시키가이샤 융합된 헤테로시클릭 화합물
PL2125786T3 (pl) * 2006-12-21 2011-07-29 Pfizer Prod Inc Bursztynian 2-((4-(1-metylo-4-(pirydyn-4-ylo)-1h-pirazol-3-ilo)fenoksy)metylo)chinoliny
WO2008124824A1 (en) * 2007-04-10 2008-10-16 Myriad Genetics, Inc. Dosages and methods for the treatment of cancer
PE20091580A1 (es) 2008-03-12 2009-11-05 Takeda Pharmaceutical Compuesto heterociclico fusionado
MX2011000306A (es) * 2008-07-08 2011-03-15 Gilead Sciences Inc Sales de compuestos inhibidores de hiv.
EP2387563B2 (en) 2009-01-16 2022-04-27 Exelixis, Inc. Malate salt of n- (4- { [ 6, 7-bis (methyloxy) quinolin-4-yl]oxy}phenyl-n' - (4 -fluorophenyl) cyclopropane-1,1-dicarboxamide, and crystalline forms thereof for the treatment of cancer
UA108618C2 (uk) 2009-08-07 2015-05-25 Застосування c-met-модуляторів в комбінації з темозоломідом та/або променевою терапією для лікування раку
US9265739B2 (en) 2010-06-02 2016-02-23 The Trustees Of The University Of Pennsylvania Methods and use of compounds that bind to HER2/neu receptor complex
US8993634B2 (en) 2010-06-02 2015-03-31 The Trustees Of The University Of Pennsylvania Methods and use of compounds that bind to Her2/neu receptor complex
US10420665B2 (en) 2010-06-13 2019-09-24 W. L. Gore & Associates, Inc. Intragastric device for treating obesity
US9526648B2 (en) 2010-06-13 2016-12-27 Synerz Medical, Inc. Intragastric device for treating obesity
US10010439B2 (en) 2010-06-13 2018-07-03 Synerz Medical, Inc. Intragastric device for treating obesity
US8628554B2 (en) 2010-06-13 2014-01-14 Virender K. Sharma Intragastric device for treating obesity
US9468681B2 (en) 2013-03-01 2016-10-18 California Institute Of Technology Targeted nanoparticles
EP3317323B1 (en) 2015-07-01 2021-05-26 California Institute of Technology Cationic mucic acid polymer-based delivery systems
US10779980B2 (en) 2016-04-27 2020-09-22 Synerz Medical, Inc. Intragastric device for treating obesity
EP3960740B1 (en) 2017-08-01 2023-11-15 Gilead Sciences, Inc. Crystalline forms of ethyl ((s)-((((2r,5r)-5-(6-amino-9h-purin-9-yl)-4-fluoro-2,5-dihydrofuran-2-yl)oxy)methyl)(phenoxy)phosphoryl)-l-alaninate (gs-9131) vanillate for treating viral infections

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6884418B1 (en) 1989-08-04 2005-04-26 Berlex Laboratories, Inc. Use of ligand-mimicking agents and anti-neoplastic drugs in cancer therapy
GB9510757D0 (en) * 1994-09-19 1995-07-19 Wellcome Found Therapeuticaly active compounds
GB9603095D0 (en) * 1996-02-14 1996-04-10 Zeneca Ltd Quinazoline derivatives
AR007857A1 (es) * 1996-07-13 1999-11-24 Glaxo Group Ltd Compuestos heterociclicos fusionados como inhibidores de proteina tirosina quinasa, sus metodos de preparacion, intermediarios uso en medicina ycomposiciones farmaceuticas que los contienen.
HUP0301120A2 (hu) * 2000-06-22 2003-08-28 Pfizer Products Inc. Szubsztituált fenilamino-kinazolin-származékok, alkalmazásuk rendellenes sejtnövekedés kezelésére és azokat tartalmazó gyógyszerkészítmények

Also Published As

Publication number Publication date
CN1608062A (zh) 2005-04-20
DOP2002000544A (es) 2003-06-16
JP2005511744A (ja) 2005-04-28
PE20030716A1 (es) 2003-08-29
MA27095A1 (fr) 2004-12-20
WO2003050108A1 (en) 2003-06-19
IS7227A (is) 2004-04-19
NO20042925L (no) 2004-09-07
TNSN04112A1 (fr) 2006-06-01
MXPA04005678A (es) 2004-12-06
AP2004003059A0 (en) 2004-06-30
GT200200272A (es) 2003-12-12
EA200400674A1 (ru) 2004-10-28
TW200301103A (en) 2003-07-01
RS46404A (en) 2006-10-27
ZA200402995B (en) 2005-04-20
PL370858A1 (en) 2005-05-30
CA2469889A1 (en) 2003-06-19
OA12735A (en) 2006-06-29
HUP0402662A2 (hu) 2005-05-30
KR20040065259A (ko) 2004-07-21
HRP20040530A2 (en) 2004-10-31
PA8561401A1 (es) 2005-02-04
EP1456199A1 (en) 2004-09-15
US20030158217A1 (en) 2003-08-21
ECSP045148A (es) 2004-07-23
JP4202926B2 (ja) 2008-12-24
EA007412B1 (ru) 2006-10-27
IL161915A0 (en) 2005-11-20
NZ532436A (en) 2006-01-27
UA75482C2 (en) 2006-04-17
AR037772A1 (es) 2004-12-01
AU2002366581A1 (en) 2003-06-23
GEP20063872B (en) 2006-07-10
BR0214876A (pt) 2004-12-28
WO2003050108A8 (en) 2003-12-18
US6844349B2 (en) 2005-01-18

Similar Documents

Publication Publication Date Title
UY27572A1 (es) Formas de sal e-2-metoxi-n-(3-(4(3-metil-4-(6-metilpiridin-3-iloxi) fenilamino) quinazolin-6-il)alil) acetamida y procedimiento de producción
AR017182A1 (es) Compuestos de aminotiazol, inhibidores de las kinasas dependientes de ciclinas y las composiciones farmaceuticas que los contienen.
BRPI0415613A (pt) novos compostos de diazaspiroalcanos e seu uso no tratamento de doenças mediadas por ccr8
EA200401114A2 (ru) Замещённые гидроксиэтиламины
BR0309167A (pt) Composto, processo para a produção de um composto, composição farmacêutica, uso do composto, método para o tratamento de um sujeito afetado por uma condição patológica ou doença e produto de combinação
BR0314393A (pt) Piperazinas heterocìclicas substituìdas para o tratamento de esquizofrenia
ATE473967T1 (de) Aminopyrazolderivate als gsk-3-inhibitoren
CU23105A3 (es) DERIVADOS NOVEDOSOS DEL áCIDO AMINODICARBOXILICO CON PROPIEDADES FARMACéUTICAS
SE0102300D0 (sv) Compounds
UY30408A1 (es) Derivados sustituidos del acetato de 8-(4-metoxifenil)-2,3,4,8-tetrahidroimidazo-[1,5-a]-pirimidin-6-amina, composiciones farmacéuticas y aplicaciones
UY30426A1 (es) Derivados sustituidos del 3-(4-metoxi-fenil)-3h-isoindol-1-ilamina trifluoroacetado, sus sales o solvatos farmaceuticamente aceptables, formulaciones farmacéuticas y aplicaciones.
BRPI0410760A (pt) compostos, processo para fabricação dos mesmos, composições farmacêuticas e uso deste compostos
UY27592A1 (es) Nuevo uso
SE0100569D0 (sv) New compounds
UY27593A1 (es) Nuevos compuestos
UY27039A1 (es) Formas de sal de amida de acido 3-(4-bromo-2,6-difluoro-benciloxi)-5-(3-(pirrolidin-1-ilbutil)ureido)isotiazol-4-carboxilico y métodos de producción
BR0013311A (pt) Derivados substituìdos de 1,5-dihidropirrol-2-ona eficazes como antagonistas de receptores nmda para o tratamento de estados de dor
BRPI0411891A (pt) pirazol[3,4-b]piridin-6-onas como inibidores de gsk-3
ATE403428T1 (de) Pyrazoloä3,4-büpyridin-6-one als gsk-3 inhibitoren
BRPI0507321A (pt) derivados de 7-amino-4-quinolona-3-ácido carboxìlico substituìdos com cicloalquila, processos para produção dos mesmos e uso dos mesmos como medicamento
ES2059929T3 (es) 1-(piridinilamino)-2-pirrolidinonas, un procedimiento para su preparacion y su uso como medicamentos.
ES2068294T3 (es) 2,3-dihidro-1-(piridinilamino)-indoles, un procedimiento para su preparacion y su uso como medicamentos.
AR042508A1 (es) Complejos de e-2-metoxi-n- ( 3 - { 4 [ 3- metil - 4- ( 6- metilpiridin-3- iloxi) fenilamino] quinazolin - 6 il } alil) acetamida
IT1307786B1 (it) Analoghi di ceramidi, processo per la loro preparazione e loro usocome antitumorali.
DE60307286D1 (de) Verfahren zur Herstellung von 2-Methyl Piperazine Derivaten.

Legal Events

Date Code Title Description
109 Application deemed to be withdrawn

Effective date: 20151110